Details

Autor(en) / Beteiligte

• Armstrong-James, Darius
• Youngs, Jonathan
• Bicanic, Tihana
• Abdolrasouli, Alireza
• Denning, David W
• Johnson, Elizabeth
• Mehra, Varun
• Pagliuca, Tony
• Patel, Brijesh
• Rhodes, Johanna
• Schelenz, Silke
• Shah, Anand
• van de Veerdonk, Frank L
• Verweij, Paul E
• White, P Lewis
• Fisher, Matthew C

Titel

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Ist Teil von

• The European respiratory journal, 2020-10, Vol.56 (4), p.2002554

Ort / Verlag

England: European Respiratory Society

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1]. Severe COVID-19 is characterised by acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated. Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections https://bit.ly/3feuGsQ